Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR 27.8 billion (USD 32.2 billion), driven by Human Pharma and Animal Health business momentum. R&D investment surged to EUR 6.4 billion (22.9% of sales), underscoring the family-owned company’s long-term innovation commitment. The Human Pharma division grew 7.4% to EUR 22.7 billion, led by Jardiance (empagliflozin) sales jumping 8.7% to EUR 8.8 billion, while 2025 launches of Hernexeos (zongertinib) and Jascayd (nerandomilast) expanded the portfolio.
Financial Highlights
Segment
2024 Net Sales
YoY Growth
Strategic Driver
Group Total
EUR 27.8B (USD 32.2B)
+7.3%
Human Pharma + Animal Health dual engines
Human Pharma
EUR 22.7B (USD 26.26B)
+7.4%
Jardiance CRM dominance + new launches
Animal Health
EUR 5.1B (implied)
—
Stable contribution
R&D Investment
EUR 6.4B (USD 7.4B)
—
22.9% of net sales – industry-leading intensity
Human Pharma R&D
EUR 5.8B
—
27.4% of segment sales – pipeline-heavy strategy
Key Product Performance
Product
2024 Sales
YoY Growth
Indication
Strategic Significance
Jardiance (empagliflozin)
EUR 8.8B (USD 10.18B)
+8.7%
CKD, T2DM, heart failure
Blockbuster anchor – CRM franchise leader
Ofev (nintedanib)
EUR 3.8B (USD 4.29B)
+5.4%
IPF, progressive fibrosing ILD
Respiratory stable growth – established standard of care
Hernexeos (zongertinib)
Launched H2 2025
—
HER2-mutant NSCLC
New oncology entrant – HER2 exon 20 insertion
Jascayd (nerandomilast)
Launched H2 2025
—
IPF
Next-gen PDE4B inhibitor – Ofev successor potential
R&D Pipeline & Strategic Focus
Therapeutic Area
Pipeline Scale
Key Focus
Cardio-Renal-Metabolic (CRM)
Multi-molecule
Jardiance combinations; SGLT2/GLP-1 synergy
Oncology
15+ projects
Zongertinib expansion; KRAS, T-cell engagers
Respiratory & Immunology
10+ projects
PDE4B franchise; biologics for severe asthma
Mental Health
5+ projects
Novel mechanisms for depression, schizophrenia
Eye Health
3+ projects
Retinal disease biologics
Total Pipeline
80+ projects, 50+ NMEs
—
Strategic Context: Family-Owned Innovation Model
Factor
Implication
R&D Intensity
22.9% of sales vs. industry average ~15% – enables long-term bets without quarterly shareholder pressure
Competitive Positioning: Private ownership enables $6.4B R&D bet on CRM + oncology while peers face margin pressure; Jardiance + Ofev cash cows fund innovation
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2025 launch performance, pipeline progression, and Jardiance market expansion. Actual results may differ due to competitive dynamics with SGLT2/GLP-1 combinations, regulatory review timelines for pipeline assets, and Animal Health market volatility.-Fineline Info & Tech
By Fineline Cube 